The relation between the blood glucose level and the FDG uptake of tissues at normal PET examinations by Henry Lindholm et al.
Lindholm et al. EJNMMI Research 2013, 3:50
http://www.ejnmmires.com/content/3/1/50ORIGINAL RESEARCH Open AccessThe relation between the blood glucose level and
the FDG uptake of tissues at normal PET
examinations
Henry Lindholm1*, Fredrik Brolin2, Cathrine Jonsson2 and Hans Jacobsson1Abstract
Background: The influence of the blood glucose level on the tracer uptake of normal tissues at
[18F]-2-fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET) was retrospectively studied in
examinations in clinical patients.
Methods: Five hundred examinations were evaluated in retrospect. The inclusion criteria were studies with a
normal or near-normal FDG distribution. Patients who had been subjected to chemotherapy (including GSF
treatment) or radiotherapy <4 weeks prior to the examination were excluded; we cannot exclude, however, that in
a very few patients the available information might have been incomplete. Otherwise, patients were included
regardless of concurrent diseases and/or therapy. In one evaluation, the mean standardized uptake value of the
liver, spleen, lungs, peripheral blood, selected muscles and bone marrow of all 500 individuals was correlated to the
blood glucose level. In another evaluation, a subgroup of 62 patients with increased blood glucose levels (≥7.0
mmol/l) was compared with another subgroup of 62 patients paired with regard to age and gender with blood
glucose levels within normal range (≤6.0 mmol/l).
Results: There was a weak positive correlation between the blood glucose level and the muscular uptake of FDG,
while there was no correlation with the tracer uptake of the liver, spleen, lungs, peripheral blood or bone marrow.
The patient group with increased blood glucose levels showed a slightly, but significantly, higher muscular FDG
uptake compared with the matched subgroup of patients with normal blood glucose levels. When comparing the
other assessed tissues/organs, there were no differences between these two patient groups.
Conclusions: The effect of hyperglycaemia at FDG PET on the studied normal tissues is restricted to a slightly increased
muscular uptake. The effect of the blood glucose level on the blood activity at the time of examination is negligible.
Keywords: Hyperglycaemia; FDG/PET; Normal tissue; SUV; Tracer distributionBackground
When clinical [18F]-2-fluoro-2-deoxy-D-glucose (FDG)
positron emission tomography (PET) was established
in the early 1990s, there were reports that hyperglycaemia
impaired the tumour uptake of FDG because of competi-
tion with endogenous blood glucose (B-glucose) [1-7]. This
led to recommendations in the European [8] and American
[9] guidelines to measure the B-glucose concentration prior
to FDG PET and reschedule patients with values exceeding* Correspondence: henry.lindholm@karolinska.se
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in any medium, provided the original work is pa certain level. While initially adhering to the recommenda-
tions, we encountered patients with elevated B-glucose
levels who were difficult to reschedule which is why they
were examined despite the evaluation. The reasons for
doing so included an urgent need for the examination, a
long travel distance for the patient and, in most cases, the
patient’s unwillingness to be rescheduled. At visual evalu-
ation the image quality of these examinations did not differ
from the image quality obtained in clinical patients with a
normal B-glucose. This observation together with a number
of subsequent reports questioning the effect of hypergly-
caemia on the distribution of FDG has increasingly caused
us to accept such patients for clinical examination.is an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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of hyperglycaemia and/or diabetes mellitus on the image
quality at FDG PET with somewhat opposing findings
[10]. Thus far, all the studies have focused on the tracer
uptake by the pathological lesion, and there has been
very little focus on the uptake by surrounding normal
tissues, even though the uptake by surrounding tissues
comprises the background activity from which the lesion
should be discerned. In this study we retrospectively
assessed the standardized uptake values (SUVs) of a
number of normal tissues/organs in clinical patients with
normal or near-normal FDG distributions and analysed the
correlation with B-glucose. The radiotracer distribution in
normal tissues/organs was also compared between two sub-
groups of patients matched with regard to age and gender;
one subgroup had increased B-glucose levels, and the other
subgroup had B-glucose levels within normal range.
Methods
Study design
FDG PET/computed tomography (CT) studies with a
normal or near-normal activity distribution were
included. All reports from clinical examinations were
retrospectively evaluated in a ‘backwards’ order. Between
September 2012 and October 2009, 500 examinations
fulfilled our inclusion criteria. Patients who had been
subjected to chemotherapy (including GSF treatment) or
radiotherapy <4 weeks prior to the examination were
excluded; we cannot exclude, however, that in a very few
patients the available information might have been
incomplete. Otherwise, patients were included irrespective
of concurrent diseases and/or therapy. Examples of
near-normal activity distributions were small, probably
benign lung lesions or radiation portals with an FDG
uptake not exceeding normal soft tissue activity,
apparent reactive normal-sized lymph nodes with a
moderately increased uptake, and a weak uptake in
surgical scars and accumulation in minor, presumably
benign skin lesions. Patients with a very small FDG
extravasation at the injection site were studied, while
individuals with larger extravasations were excluded.
Similarly, only patients with a minute brown adipose
tissue uptake were included. Patients with a visually
apparent generally increased muscular uptake as previously
studied by us were not included [11]. No patient with
evidence of active malignancy was studied.
In the first evaluation, the correlation between the
blood glucose level and SUVmean of various normal
tissues was assessed in all 500 patients. In the second
evaluation, patients with a B-glucose ≥7.0 mmol/l
(increased) were paired with regard to age and gender
with patients with a B-glucose ≤6.0 mmol/l (normal). Of
75 patients with an increased B-glucose, 62 patients could
be matched with normals and were studied.Patients
In the first evaluation, all 500 patients were studied. The
mean age was 58 years (range 11 to 89). There were 248
males and 252 females. Mean B-glucose was 6.0 mmol/l
(±SD 1.6). The second (paired) evaluation comprised
62 + 62 patients with a mean age of 65 years (range
25 to 80), including 33 males and 29 females in each
group. In the patients with an increased B-glucose, the
mean B-glucose concentration was 9.0 mmol/l (±SD 2.0)
and the mean body mass index (BMI) was 26.5 kg/m2
(±SD 4.9). Of these patients, 26 were known diabetics, 13
of whom were on insulin treatment. In the controls, the
mean B-glucose concentration was 5.2 mmol/l (±SD 0.6)
and the mean BMI was 24.3 kg/m2 (±SD 3.3). One of
these patients was a known diabetic on insulin treatment.
There was a strongly significant difference of the B-glucose
between the two subgroups (p < 0.0001). This retrospective
investigation was approved by the regional ethics
research committee (Regionala etikprövningsnämnden i
Stockholm, Karolinska Institutet, SE-171 77 Stockholm,
Sweden; unique identifying numbers 2009/1491-31/2 and
2012/1434-32).
PET/CT examinations
B-glucose was measured immediately prior to administra-
tion of FDG using the same glucometer, HemoCue®
Glucose 201+ (Hemocue AB, Ängelholm, Sweden).
A Biograph 64 TruePoint TrueV PET/CT scanner
(Siemens Medical Solutions, Erlangen, Germany) was used.
The examination was performed according to the European
guidelines, although patients with increased B-glucose were
not rescheduled [8]. FDG (4 MBq/kg body weight) was
administered intravenously (i.v.). The examination was
performed approximately 1 h thereafter. It usually included
the mid-skull to the proximal thigh. Prior to examination
with i.v. contrast medium, a low-dose CT was performed
for attenuation and scatter correction. Directly thereafter,
the PET examination was done, followed by a diagnostic
(full-current) CT with or without i.v. contrast medium. At
examinations without i.v. contrast medium, the full-dose
CT was used for attenuation and scatter correction.
The diagnostic CT examinations were performed with
a tube tension of 120 kV, a pitch of 0.8, a slice thickness
of 1.2 mm and a rotation speed of 0.5 s. The current
was set to 160 mAs (reference), and dose modulation
(CARE Dose4D) was applied. In the examinations done
only for photon attenuation and scattering correction,
CT was performed with a tube tension of 120 kV, a pitch
of 0.8, a slice thickness of 1.2 mm, a rotation speed of
0.5 s and a current of 50 mAs. CT acquisitions were
always done with the breath-holding technique at a mean
inspiratory level.
There was a mean of 61 min (range 50 to 70 min)
between tracer administration and PET registration.
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position during normal tidal breathing. The PET data
were subsequently reconstructed with the manufacturer’s
2D-OSEM algorithm (four iterations and eight subsets)
using a 5-mm post-reconstruction Gaussian filter. The
image matrix size was 168 × 168 with a slice thick-
ness of 5 mm. In addition to attenuation and scatter
correction, all data were corrected for dead time and
random coincidences.
Image analysis
Activity quantification was done in the PET images
using Siemens syngo MultiModality Workplace (syngo
MMWP, VE36A). Volumes of interest (VOIs) of different
sizes and shapes adapted to the various organs/tissues
were drawn manually, avoiding margins.
The definition in the images of the various VOIs was
done by combining the information from both the CT
and PET acquisitions. SUVmean of the liver was calcu-
lated by averaging the values of VOIs with a volume of
20 to 50 cm3 allocated at the centre of the right and left
liver lobes, respectively. SUVmean of the spleen was
similarly averaged from three elliptical VOIs with a
volume of 4 to 8 cm3 in various portions of the organ.
Muscular SUVmean was calculated by averaging the
values of elliptical VOIs allocated in the right and left
shoulder muscles (25 to 50 cm3), in both psoas muscles
(5 to 10 cm3) and in the right and left gluteal muscles
(25 to 50 cm3), respectively. SUVmean of the lungs was
calculated by averaging the values of parasagittal, ‘flat’
VOIs with a volume of 25 to 50 cm3 in each lung, cover-
ing both the upper and lower lobes. Blood SUVmean
was assessed by averaging the activity of five VOIs with
a volume of 0.8 to 2 cm3 allocated in different portions
of the lumen of the large mediastinal vessels. As they
could not be discerned from the diffuse mediastinal
FDG activity in most patients, allocation of these VOIs
was done using the CT images. In cases of increased
activity of the vessel wall, this was avoided. Bone marrow
SUVmean was calculated by averaging the values of
elliptical VOIs with a volume of 2 to 5 cm3 allocated in
both iliac crests and spherical VOIs with a volume of 1
to 1.5 cm3 in each lumbar vertebral body. If a vertebra
was not possible to evaluate because of a compression
or extensive spondylosis, for example, it was excluded.
In a few studies, one or two of the lower dorsal vertebrae
were included instead.
Statistical methods
The distribution of the data showed that the correlation
between B-glucose and SUVmean of the various organs/
tissues could be analysed by Pearson’s correlation coeffi-
cient, applicable for linear associations. SUVmean of the
muscles showed a skewed distribution (>1), which is whya reciprocal transformation was carried out prior to the
analysis. Otherwise, such corrections were not done. A
correlation coefficient of 0 to 0.25 indicates little or no
relationship. Correlation coefficients between 0.25 and
0.50 indicate a fair degree of relationship, those between
0.50 and 0.75 indicate a moderate to good relationship and
those >0.75 indicate a very good to excellent relationship
[12]. The coefficient of determination (R2) indicates the
proportion of the total variation in SUVmean that is
explained by the variable studied, i.e. B-glucose.
The distribution of the data allowed for the use of
Student’s two-tailed t test for independent samples for
assessing the difference in SUVmean between the
patients with increased B-glucose and the patients with
normal B-glucose. The Mann–Whitney U test was
applied to compare the B-glucose level of the two
subgroups as the variable was not normally distributed.
P < 0.05 was considered statistically significant.
Results
In the analysis of the entire patient group, the skeletal
muscles were distinct from the other organs/tissues
(Table 1). The correlation coefficient (0.24) for skel-
etal muscles indicated an almost fair relationship with
B-glucose, corresponding to an R2 of 0.06. The correlation
coefficients for the other organs/tissues were much lower
(0.01 to 0.14), although a significant difference from zero
indicated a certain correlation for the liver, spleen and
blood. The R2 for the organs/tissues other than the
skeletal muscles was very low (0.00 to 0.02).
In comparing the patients with normal B-glucose
values with the patients with increased values, the latter
group showed a higher muscular FDG uptake (Table 2).
The difference was very small but nevertheless significant.
Otherwise, there were no significant differences between
these two patient groups.
Discussion
Normal phenomena should ideally be studied in normal
individuals. As this is not possible when a large number
of individuals must be studied, clinical patients who are
considered normal have to serve as subjects. Since the
FDG distribution seems to be a zero-sum game [11],
only patients with normal PET findings should ideally
have been studied. This turned out to be difficult since
few clinical patients show a completely normal FDG
distribution. Consequently, examinations showing a minor
uptake, which is assumed to have a negligible effect on the
FDG distribution, were included. The shortcomings of
basing the study on clinical patients should be well
compensated for the large number of observations.
SUV assessments are strongly influenced by the partial
volume effect, which in small lesions will lead to an under-
estimation of the uptake. In the current PET system, a VOI
Table 1 Correlation between blood glucose concentration and mean SUVmean of various normal tissues/organs at
FDG PET examination
Liver Spleen Lungs Blood Muscles Bone marrow
Correlation coefficient 0.14 0.10 0.01 0.12 0.24 0.06
Significance (p) 0.001 ≤ p < 0.01 0.01 ≤ p < 0.05 ns 0.001 ≤ p < 0.01 <0.001 ns
R2 0.019 0.010 0.000 0.014 0.055 0.004
ns, not significant.
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of ≥2 cm (4.2 cm3) is necessary for an adequate recovery of
the uptake. This should be the case in the assessments of
the liver, lungs, muscles, iliac crests and, in most
patients, the spleen, while in many patients the size
of the mediastinal vessels and the vertebral bodies is
not sufficient. However, this fact should hardly affect
our findings because of the comparative nature of the
study and, not least, the large number of observations.
The cut-off values used for defining the two patient
groups in the second part of the study were chosen to
distinguish clearly between the two groups in order to allow
for an optimal comparison of the effects of B-glucose. They
were not related to any values regarding the rescheduling
of patients for examination.
The current study was inspired by a recent report that
a high serum glucose concentration does not predict
poor image quality in FDG PET/CT, which confirmed a
growing impression of ours [13]. A reduction in the
FDG uptake of the brain at increased B-glucose values
has been convincingly demonstrated [2,14,15]. There is
also a well-known opposite effect on the myocardial
uptake of FDG [16]. With the exception of these two
tissues, previous studies of the effects of B-glucose and/or
diabetes on the accumulation of FDG in normal tissues
are not consistent. All such studies have also been
performed in much smaller patient cohorts than in the
present investigation. An increased background activity
with a consequent lowered image quality was reported in
a series of patients with pancreatic cancer who were
subjected to chronic hyperglycaemia [6]. Another
study of patients with the same condition showed a
reduced sensitivity of various malignancies but not of
inflammatory lesions [10]. After glucose loading, an
increased background activity leading to a lowered
image quality was reported in a series of patients withTable 2 Mean SUVmean (±SD) of various normal organs/tissu
Liver Spleen Lungs
Increased B-glucose 2.5 (0.45) 1.8 (0.38) 0.4 (0.13
Significance (p) ns ns ns
Normal B-glucose 2.4 (0.37) 1.7 (0.28) 0.4 (0.12
Sixty-two patients with increased blood glucose concentrations (≥7.0 mmol/l) were
normal blood glucose (≤6.0 mmol/l) levels. ns, not significant.colorectal tumours [17], as well as a somewhat more
muscular FDG uptake in a number of patients with
head and neck cancer [3]. In contrast to these findings,
there are two studies reporting no effects on the soft tissue
background activity with chronically increased B-glucose in
tumour patients [18,19]. In another clinical study, chronic
hyperglycaemia did not affect the FDG uptake in the liver
or muscles, while the brain uptake decreased [14]. A similar
finding was reported in rats after a glucose load [15].
Another study in rats with experimentally induced
hyperglycaemia showed higher FDG activity in the
blood compared to controls and a much lower brain
uptake, while the muscular activity was insignificantly
affected [2]. In summary, in cases of an effect exerted
by increased B-glucose, a higher uptake by normal tissues
outside the brain is reported. It also seems that the
FDG uptake of normal tissues is affected more by
acute (experimentally induced) hyperglycaemia than
by chronic hyperglycaemia [14].
The key finding of this study is the higher FDG uptake
of the muscles with increased B-glucose, which was found
in both evaluations. The effect is weak but is distinct from
the effect on other tissues where the correlations can, in
principle, be disregarded and considered to be caused by
the very large number of observations. The described
effect is in line with previous reports since the patients
with increased B-glucose in this study were not subjected
to induced hyperglycaemia and in most cases must be
considered to be suffering from chronic hyperglycaemia.
The conclusion is that the effect of increased B-glucose on
the FDG uptake of various normal tissues can be ignored
in clinical examinations.
The tendency toward a correlation between B-glucose
and the FDG activity of the muscles is a clear finding
and is line with most previous reports. It is, however,
not consistent with the theory of a pure competitiones in clinical patients at FDG PET examination
Blood Muscles Bone marrow
) 1.6 (0.39) 0.9 (0.21) 1.5 (0.37)
ns 0.001 ≤ p < 0.01 ns
) 1.6 (0.29) 0.8 (0.18) 1.4 (0.30)
compared with 62 patients matched with regard to age and gender, with
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lower tracer uptake by various ‘indifferent’ tissues. Such
a straightforward mechanism is also contradicted by the
negligible effect of B-glucose on the blood activity, which
is a fundamental finding of the study. A competition
between FDG and endogenous B-glucose would give rise
to an increased blood activity with an increased B-glucose.
The cellular glucose uptake is a complex mechanism
influenced by several insulin-dependent as well as non-
insulin-dependent factors, but a thorough analysis of this
mechanism is beyond the scope of this work. Like glucose,
the transfer of FDG into the cells is mediated by the
glucose transporters 1 to 7 (Glut1 to Glut7) and the
sodium-glucose-linked transporters 1 to 2 [10]. Most
glucose transporters are expressed in a tissue-specific
manner. Interestingly, there is a large expression of Glut4
transporters in fat, skeletal muscle and heart [20,21], and
thus, the latter two tissues show an increased FDG activity
with increased B-glucose.
Conclusions
The effect of hyperglycaemia at FDG PET on the studied
normal tissues is restricted to a slightly increased muscular
uptake. The effect of the blood glucose level on the blood
activity at the time of examination is negligible.
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